

JAN 1 3 2003

Page 1 of 3 KO23459

Premarket Notification 510(k) Summary As required by section 807.92 Datex-Ohmeda S/5 Entropy Module, M-ENTROPY and Accessories

GENERAL COMPANY INFORMATION as required by 807.92(a)(1)

COMPANY NAME/ADDRESS/PHONE/FAX:

Datex-Ohmeda 86 Pilgrim Road Needham, MA 02492 USA Tel: 781-449-8685 Fax: 781-433-1344

NAME OF CONTACT:

Mr. Joel Kent

DATE:

October 11, 2002

DEVICE NAME as required by 807.92(a)(2)

TRADE NAME:

Datex-Ohmcda S/5 Entropy Module, M-ENTROPY and Accessories

COMMON NAME:

EEG and FEMG Measurement Module with Entropy variables

CLASSIFICATION NAME:

The following Class II classifications appear applicable:

Electroencephalograph 882.1400 OLW, ORT, GKY, DMC

NAME OF LEGALLY MARKETED DEVICE FOR WHICH A CLAIM OF SUBSTANTIAL EQUIVALENCE IS MADE as required by 807.92(a)(3)

The Datex-Ohmeda Entropy Module, M-ENTROPY and accessories is substantially equivalent in safety and effectiveness to the legally marketed predicate Datex-Ohmeda S/5TM BIS module M-BIS (K013389).

DEVICE DESCRIPTION as required by 807.92(a)(4)

The Datex-Ohmeda Entropy module, M-ENTROPY is a single-width plug-in parameter module for a Datex-Ohmeda modular monitoring system. The Datex-Ohmeda Entropy module, M-ENTROPY can be used with the following Datex-Ohmeda modular monitors: S/5TM Anesthesia Monitor (AM) with main software L-ANE03(A)..00 or newer version, and S/5TM Compact Anesthesia Monitor (CAM) with main software L-CANE03(A)...00 or newer version. Entropy is an innovative monitoring modality which is designed to provide information on the electrical activity of the CNS during general anesthesia. Entropy monitoring is based on acquisition, and processing of raw EEG and FEMG signals by using the Entropy algorithm. The entropy algorithm is a Datex-Ohmeda application of spectral entropy based on information theory. The Datex-Ohmeda Entropy Module for the Datex-Ohmeda S/5TM Monitoring system may be used as an aid in monitoring the effects of certain anesthetic agents. The Datex-Ohmeda Entropy sensor is a rectangular shaped, pre-gelled array of three (3) Zipprep® electrodes that is applied to the patient's skin to record electrophysiological (such as EEG) signals. It is a low impedance, single patient use, disposable sensor that is designed for application to the frontal / temporal area. The Datex-Ohmeda Entropy sensor is designed to provide ease of use and electrode placement accuracy. The sensor is used in conjunction with M-ENTROPY. The Datex-Ohmeda Entropy sensor cable connects the Entropy sensor to the M-ENTROPY module both mechanically and electrically.

Calculated parameters are:

- Response Entropy, RE (range 0-100), continuous processed variable for fast detection of activation of facial muscles, i.e. FEMG.
- State Entropy, SE (range 0-91), continuous processed variable calculated from the EEG. SE is
 designed to be sensitive to the hypnotic effect of anesthetic drugs in the brain.
- Burst Suppression Ratio, BSR (range=0-100%), the percentage of epochs in the past 60 seconds in which the EEG signal is considered suppressed.

All the calculated parameters can be selected on the display, and trended. The raw EEG signal can be displayed from one of the two monitored channels. The waveform size, color and sweep speed can be adjusted. Alarms for Entropy are taken care of by the host monitor and follow the user interface for alarms in Datex-Ohmeda S/5 patient monitors. There are auditory and visual alarms and user adjustable limits for Entropy variables. The default is OFF, because the device does not provide information to be used for treatment or therapy.

INTENDED USE as required by 807.92(a)(5)

Intended use:

The Datex-Ohmeda Entropy module, M-ENTROPY and accessories are intended to be used with Datex-Ohmeda modular multiparameter monitors for monitoring the neurophysiological status of hospitalized patients.

Indications for use:

The Datex-Ohmeda Entropy Module is indicated for monitoring the state of the central nervous system (CNS) by data acquisition of electroencephalograph (EEG) and frontal electromyograph (FEMG) signals in the anesthesia environment. The spectral entropies, State Entropy (SE) and Response Entropy (RE), are processed EEG and FEMG variables, and may be used as an aid in monitoring the effects of certain anesthetic agents. The Entropy module is indicated for use by qualified medical personnel only.

SUMMARY OF TECHNOLOGICAL CHARACTERITICS OF DEVICE COMPARED TO THE PREDICATE DEVICE as required by 807.92(a)(6)

The Datex-Ohmeda Entropy module, M-ENTROPY is a single-width plug-in parameter module for a Datex-Ohmeda modular monitoring system. The Datex-Ohmeda Entropy module, M-ENTROPY can be used with the following Datex-Ohmeda modular monitors: S/5TM Anesthesia Monitor (AM) with main software L-ANE03(A)..00 or newer version, and S/5™ Compact Anesthesia Monitor (CAM) with main software L-CANE03(A)..00 or newer version. The predicate Datex-Ohmeda BIS module, M-BIS can be used with the following Datex-Ohmeda modular monitors: S/5 Anesthesia Monitor(AM), S/5 Compact Anesthesia Monitor (CAM), S/5 Critical Care Monitor (CCM) and S/5 Compact Critical Care Monitor (CCCM) with main software L-ANE02(A)..00 or L-ICU02(A)..00 or newer version. M-ENTROPY and the predicate M-BIS are modules that are used to calculate parameters from electroencephalograph (EEG) and frontal electromyograph (FEMG) signals. M-ENTROPY provides two spectral entropy parameters State Entropy (SE) and Response Entropy (RE). Whereas M-BIS provides Bispectral Index (BIS), Signal Quality Index (SQI), Suppression Ratio (SR) and Electromyography (EMG) variables. The sensors used for M-ENTROPY and M-BIS measurements are based on similar electrode technology. The sensor placement is similar, but the graphical printing is different. Mechanically M-ENTROPY and M-BIS modules are similar, but M-BIS has separate preamplifier (headbox), whereas M-ENTROPY has the preamplifier built-in to the module. The comparison above shows that there are no new questions of safety and effectiveness for the Datex-Ohmeda Entropy module M-ENTROPY.

SUMMARY OF NONCLINICAL TESTING FOR THE DEVICE and CONCLUSIONS as required by 807.92(b)(1)(3)

The Datex-Ohmeda Entropy Module, M-ENTROPY and accessories complies with the safety standards below and is therefore safe and effective for the intended use. The device has been thoroughly tested including electrical safety, electromagnetic compatibility, mechanical and environmental tolerance, software validation and verification of specifications. Verification of compliance with the following mandatory and voluntary standards has been made:

- IEC 60601-1:1988 + Amdt. 1:1991 + Amdt. 2:1995 (Part 1: General requirements for safety)
- EN 60601-1:1990+ A1:1993 + A13:1996 + A2:1995 (identical to IEC60601-1:1988 + Amdt. 1:1991 + Amdt. 2:1995)
- CAN/CSA C22.2 No. 601.1-M90 + S1:1994 (Canadian deviations to IEC 60601-1:1988 + Amdt. 1:1991)
 + S2:1998 (=IEC Amdt 2:1995)
- UL 2601-1, October 24, 1997 (U.S. deviations to IEC 60601-1:1988 + Amdt. 1:1991+ Amdt. 2:1995)
- AAMI ES1-1993 (Safe current limits for electromedical apparatus)
- Electroencephalograph Devices Guidance for 510(k) Draft Document Version 1.0 November 3, 1997
- IEC 601-2-26 Medical electrical equipment. Part 2: Particular requirements for the safety of electroencephalographs 04/01/94
- ISO 14971 Ed. 1: Medical devices Application of risk management to medical devices
- FDA Performance standard, 21 CFR Part 898.12 PERFORMANCE STANDARD FOR ELECTRODE LEAD WIRES AND PATIENT CABLES

Conclusion:

The summary above shows that there are no new questions of safety and effectiveness for the Datex-Ohmeda Entropy Module, M-ENTROPY and accessories as compared to the predicate device.

DEPARTMENT OF HEALTH & HUMAN SERVICES



Food and Drug Administration 10903 New Hampshire Avenue Document Control Room –WO66-G609 Silver Spring, MD 20993-0002

Datex-Ohmeda Joel Kent Manager, Quality and Regulatory Affairs 86 Pilgrim Road Needham, Massachusetts 02492

APR - 9 2012

Re: K023459

Trade/Device Name: Datex-Ohmeda S/5 Entropy Module, M-Entropy and Accessories

Regulation Number: 21 CFR 882.1400 Regulation Name: Electroencephalograph

Regulatory Class: II

Product Code: OLW, ORT, GXY, OMC Dated (Date on orig SE ltr): October 11, 2002 Received (Date on orig SE ltr): October 15, 2002

Dear Mr. Kent:

This letter corrects our substantially equivalent letter of January 13, 2003.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Malvina B. Eydelman, M.D.

Director

Division of Ophthalmic, Neurological, and Ear, Nose and Throat Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

510(k) Number (if known):	<u> </u>	59
Device Name: <u>Datex-Ohm</u>	eda S/5™ Entrop	y Module (M-ENTROPY) and accessories
nervous system (CNS) by d electromyograph (FEMG) s Entropy (SE) and Response	ata acquisition of ignals in the anes Entropy (RE), ar ring the effects of	cated for monitoring the state of the central felectroencephalograph (EEG) and frontal sthesia environment. The spectral entropies, State processed EEG and FEMG variables, and mad fertain anesthetic agents. The Entropy modusonnel only.
(PLEASE DO NOT WRITE NEEDED)	BELOW THIS I	LINE - CONTINUE ON ANOTHER PAGE IF
Concurrence	ce of CDRH, Off	ice of Device Evaluation (ODE)
Prescription Use (Per 21 CFR 801.109)	OR	Over-The-Counter Use
		(Optional Format 1-2-96)
la and	lash of	Milkerson
	n Sign-Off) of General, l	· ·
	rological Dev	K023459
	Number	7007131